Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.

Nassiri F, Patil V, Yefet LS, Singh O, Liu J, Dang RMA, Yamaguchi TN, Daras M, Cloughesy TF, Colman H, Kumthekar PU, Chen CC, Aiken R, Groves MD, Ong SS, Ramakrishna R, Vogelbaum MA, Khagi S, Kaley T, Melear JM, Peereboom DM, Rodriguez A, Yankelevich M, Nair SG, Puduvalli VK, Aldape K, Gao A, López-Janeiro Á, de Andrea CE, Alonso MM, Boutros P, Robbins J, Mason WP, Sonabend AM, Stupp R, Fueyo J, Gomez-Manzano C, Lang FF, Zadeh G. · 2023

Read Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. by Nassiri F, Patil V, Yefet LS, Singh O, Liu J, Dang RMA, Yamaguchi TN, Daras M, Cloughesy TF, Colman H, Kumthekar PU, Chen CC, Aiken R, Groves MD, Ong SS, Ramakrishna R, Vogelbaum MA, Khagi S, Kaley T, Melear JM, Peereboom DM, Rodriguez A, Yankelevich M, Nair SG, Puduvalli VK, Aldape K, Gao A, López-Janeiro Á, de Andrea CE, Alonso MM, Boutros P, Robbins J, Mason WP, Sonabend AM, Stupp R, Fueyo J, Gomez-Manzano C, Lang FF, Zadeh G. (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc10287560.txt.

Introduction

Nassiri and a large trial team report a phase one and two trial of a virus therapy plus an immune drug in recurrent glioblastoma, in a 2023 study. Glioblastoma is a fast-growing brain tumor that nearly always returns after standard care. The treatment paired DNX-2401, a virus engineered to attack tumor cells, with pembrolizumab, a drug that frees the immune system.

The virus was injected into the tumor, followed by the immune drug. The paper reports safety and survival results for the combination. The approach tests whether a virus can turn a cold tumor hot for immunotherapy.

Catalog record

CREATORNassiri F, Patil V, Yefet LS, Singh O, Liu J, Dang RMA, Yamaguchi TN, Daras M, Cloughesy TF, Colman H, Kumthekar PU, Chen CC, Aiken R, Groves MD, Ong SS, Ramakrishna R, Vogelbaum MA, Khagi S, Kaley T, Melear JM, Peereboom DM, Rodriguez A, Yankelevich M, Nair SG, Puduvalli VK, Aldape K, Gao A, López-Janeiro Á, de Andrea CE, Alonso MM, Boutros P, Robbins J, Mason WP, Sonabend AM, Stupp R, Fueyo J, Gomez-Manzano C, Lang FF, Zadeh G.
YEAR2023
COLLECTIONPAPERS
FORMATTXT
FILE SIZE67 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC10287560

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial By Farshad Nassiri, Vikas Patil, Leeor S. Yefet, Olivia Singh, Jeff Liu, Rachel M. A. Dang, Takafumi N. Yamaguchi, Mariza Daras, Timothy F. Cloughesy, Howard Colman, Priya U. Kumthekar, Clark C. Chen Published in: Nature Medicine DOI: 10.1038/s41591-023-02347-y ABSTRACT Immune-mediated anti-tumoral responses, elicited by oncolytic viruses and augmented with checkpoint inhibition, may be an effective treatment approach for glioblastoma. Here in this multicenter phase 1/2 study we evaluated the combination of intratumoral delivery of oncolytic virus DNX-2401 followed by intravenous anti-PD-1 antibody pembrolizumab in recurrent glioblastoma, first in a dose-escalation and then in a dose-expansion phase, in 49 patients. The primary endpoints were overall safety and objective response rate. The primary safety endpoint was met, whereas the primary efficacy endpoint was not met. There were no dose-limiting toxicities, and full dose combined treatment was well tolerated. The objective response rate was 10.4% (90% confidence interval (CI) 4.2–20.7%), which was not statistically greater than the prespecified control rate of 5%. The secondary endpoint of overall survival at 12 months was 52.7% (95% CI 40.1–69.2%), which was statistically greater than the prespecified control rate of 20%. Median overall survival was 12.5 months (10.7–13.5 months). Objective responses led to longer survival (hazard ratio 0.20, 95% CI 0.05–0.87). A total of 56.2% (95% CI 41.1–70.5%) of patients had a clinical benefit defined as stable disease or better. Three patients completed treatment with durable responses and remain alive at 45, 48 and 60 months. Exploratory mutational, gene-expression and immunophenotypic analyses revealed that the balance between immune cell infiltration and expression of checkpoint inhibitors may potentially inform on response to treatment and mechanisms of resistance. Overall, the combination of intratumoral DNX-2401 followed by pembrolizumab was safe with notable survival benefit in select patients (ClinicalTrials.gov registration: NCT02798406). MAIN Glioblastoma is the most common and lethal adult primary brain tumor. The standard of care treatment for newly diagnosed patients includes surgical resection followed by concomitant chemoradiotherapy and adjuvant temozolomide1. Despite maximal multimodal therapy, patients invariably experience recurrence of their disease 7 months after diagnosis, on average1. Unfortunately, treatment options at recurrence are scarce. Existing salvage therapies have very limited efficacy, with median survival being in the range of only 6–8 months after tumor progression2. Effective treatments for recurrent disease are urgently needed. While immune checkpoint blockade by anti-PD1 or anti-PD-L1 antibodies have improved outcomes with objective responses in a variety of other cancers, including those in the brain such as metastatic melanoma3, they have had limited efficacy as monotherapy for recurrent glioblastoma where the microenvironment is innately immunosuppressive (that is, immunologically ‘cold’)4,5. Oncolytic viruses are capable of reconditioning the tumor microenvironment toward a ‘hot’ phenotype, providing rationale for combinatorial therapy with checkpoint inhibitors, which has been shown to improve outcomes in other cancers6,7. DNX-2401 (tasadenoturev; Delta-24-RGD) is a conditionally replicative oncolytic adenovirus engineered to treat high-grade malignant gliomas8,9. The virus contains two stable genetic changes in the adenovirus dsDNA genome that cause it to selectively and efficiently replicate in cancerous cells. A dose-escalation phase 1 study demonstrated that stereotactic delivery of DNX-2401 into patients with high-grade gliomas was safe and induced cell death initially by direct oncolysis and subsequently by antitumor response from infiltrated immune cells, with durable responses after a single intratumoral dose10. In this Article, we report the results of CAPTIVE (2401BT-002P; KEYNOTE-192; NCT02798406), a two-part, phase 1/2, multicenter, open-label clinical trial of combined intratumoral injection of DNX-2401 with systemic pembrolizumab for patients with recurrent glioblastoma. This is the first in-human investigation of combined oncolytic virus with immune checkpoint blockade for recurrent glioblastoma. RESULTS Patient demographics and baseline characteristics A total of 49 patients from 13 of the 15 participating institutions were enrolled between 28 September 2016 and 17 January 2019 (Fig. 1a). The demographic and baseline clinical characteristics of all patients enrolled are reported in Table 1. The median age of patients was 53 years, and 41% were women. The majority of patients (80%) presented after first recurrence, and 18% of patients were using steroids at baseline. All patients had histopathological diagnosis of glioblastomas, except one patient enrolled with gliosarcoma (2%). Most patients (90%, N = 44) had reported IDH1 wild-type tumors, four (8%) had IDH1 mutant tumors and IDH1 mutation status was not known for one patient. All patients had received prior treatment with temozolomide and radiotherapy, six (12%) patients had prior bevacizumab treatment and five (10%) had prior treatment with a tumor-treating fields device.Fig. 1Survival and response to treatment.a, Patient flow in trial. b, Waterfall plot that displays the maximal change in tumor size for all patients who received full-dose DNX-2401 treatment (n = 42). Bars represent the maximal tumor change from baseline on the basis of contrast-enhanced MRI. Bars are colored according to responses classified according to mRANO criteria. c, Survival for each patient by DNX-2401 dose. The bar colors show the response to treatment according to the mRANO criteria. Arrows indicate that the patient remains alive. d, Overall survival for the intent to treat population. Crosses denote censored data.Table 1Patient demographics and baseline characteristicsCharacteristicPatients (N = 49), no. (%)Median age (range), years53 (26–73)Sex Female20 (41%) Male29 (59%)Diagnosis at enrollment Glioblastoma48 (98%) Gliosarcoma1 (2%)Karnofsky Performance Score 10010 (20%) 9028 (57%) 806 (12%) 705 (10%)Recurrences before treatment 139 (80%) 210 (20%)Baseline tumor size Median maximum diameter (range), mm28.5 (11.0–48.2) Median tumor area (range), mm2597.2 (110.0–1599.8)IDH1 R132 status Mutant4 (8%) Wild type44 (90%) Unknown1 (2%)MGMT gene promoter methylation status Methylated14 (29%) Unmethylated28 (57%) Unknown7 (14%)Prior therapies Surgical resection44 (90%) Radiotherapy49 (100%) Temozolomide49 (100%) Bevacizumab6 (12%) Tumor treating fields5 (10%)Baseline dexamethasone use ≥1.5 mg per day Yes9 (18%) No40 (82%) Safety Forty-eight of 49 (98%) patients were treated with one dose of DNX-2401 after a standard biopsy, which was then followed by pembrolizumab starting 7 days later. One patient enrolled in the first dose cohort received 5 × 108 viral particles (v.p.) DNX-2401 but did not start pembrolizumab due to delirium, which was attributed by the investigators to anesthesia used during biopsy, unrelated to treatment. This patient was included in the safety analysis set only, per protocol. There were no dose-limiting toxicities observed, and the maximal dose tested (5 × 1010 v.p. DNX-2401) was selected as the declared dose for the dose-expansion phase. In total, across both dose-escalation and dose-expansion phases, patients were treated with 5 × 108 (n = 4), 5 × 109 (n = 3) and 5 × 1010 v.p. DNX-2401 (n = 42). The median duration of exposure to treatment with DNX-2401 and pembrolizumab was 153 days (range 21–753 days), including three patients (6%) who completed the full 2 year course of pembrolizumab therapy. An overview of adverse events (AEs) in the study is summarized in Extended Data Tables 1 and 2 and Supplementary Table 1. Overall, DNX-2401 in combination with pembrolizumab was generally well tolerated and AEs were primarily as expected for patients with recurrent glioblastoma, with the majority of these being grade 3 or lower events. There were no AEs related to adenoviral infection. There were no deaths related to AEs that were related to treatment. One patient died approximately 7 months after initiating treatment due to hyperosmolar hyperglycemic nonketotic acidosis, which was considered unrelated to treatment. AEs

Read the complete text